Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/13/2017 |
| Start Date: | January 2004 |
| End Date: | August 2006 |
Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Many individuals with schizophrenia smoke cigarettes but little is known about the factors
that control smoking in people with schizophrenia. The purpose of this trial is to evaluate
how bupropion, an antidepressant medication, affects smoking behaviors in individuals with
schizophrenia who smoke.
that control smoking in people with schizophrenia. The purpose of this trial is to evaluate
how bupropion, an antidepressant medication, affects smoking behaviors in individuals with
schizophrenia who smoke.
There is a high prevalence of cigarette smoking among people with schizophrenia and few
smoking cessation interventions have been developed for these individuals. Bupropion is an
antidepressant medication commonly used to treat smoking in smokers without psychiatric
disorder. This study compares how smokers with schizophrenia and smokers without psychiatric
illness respond to bupropion (0, 300 mg/day).
Participants will be randomly assigned to receive either bupropion or placebo. Study visits
will occur after one-week treatment with placebo or bupropion. During study sessions,
participants will come to the laboratory at 9 am and will remain abstinent in the laboratory
for 5 hrs. Participants will then be assessed for craving and withdrawal symptoms after
viewing and handling neutral cues and smoking cues. After that, participants will have a
90-min period to smoke, and smoking topography will be measured.
smoking cessation interventions have been developed for these individuals. Bupropion is an
antidepressant medication commonly used to treat smoking in smokers without psychiatric
disorder. This study compares how smokers with schizophrenia and smokers without psychiatric
illness respond to bupropion (0, 300 mg/day).
Participants will be randomly assigned to receive either bupropion or placebo. Study visits
will occur after one-week treatment with placebo or bupropion. During study sessions,
participants will come to the laboratory at 9 am and will remain abstinent in the laboratory
for 5 hrs. Participants will then be assessed for craving and withdrawal symptoms after
viewing and handling neutral cues and smoking cues. After that, participants will have a
90-min period to smoke, and smoking topography will be measured.
Inclusion Criteria:
- Diagnosed with schizophrenia or schizo-affective disorder
- Smokes between 20 and 50 cigarettes per day
- Moderate to high nicotine dependence score
- Interest in quitting smoking
Exclusion Criteria:
- Currently trying to quit smoking
- Seizure disorder or lowered seizure threshold due to anorexia, bulimia, head trauma,
diabetes with insulin, or hypoglycemics
- Alcohol or drug use disorders
- Requires certain medications
- Pregnant or breastfeeding
We found this trial at
2
sites
Click here to add this to my saved trials
Brown University Located in historic Providence, Rhode Island and founded in 1764, Brown University is...
Click here to add this to my saved trials